secwatch.observer — SEC 8-K summary
======================================

Issuer:     Passage BIO, Inc. (PASG)
CIK:        0001787297
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001104659-24-084615
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Passage Bio out-licenses three pediatric gene therapy programs to GEMMABio, extends cash runway to Q2 2026
--------------------------------------------------------------------------------

- Out-licensed PBGM01, PBKR03, PBML04 to GEMMABio; initial $10M + up to $124M milestones + royalties.
- Cash of ~$91.8M at June 30, 2024; operating runway extended to end of Q2 2026.
- CMO Mark Forman resigned effective Aug 2, 2024; no disagreement with company.
- Appointed Susan Browne as CSO and Stuart Henderson as CBO effective Aug 1, 2024.
- Entered new collaboration with GEMMABio to advance CNS programs including Huntington's disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787297/000110465924084615/0001104659-24-084615-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787297/000110465924084615/tm2420570d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-084615

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer